Provectus Biopharmaceuticals, Inc. (PVCT)

PVCT Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0.56	0.99	0	0	0
Revenue Growth (YoY)	-43.61%	-	-	-	-
Cost of Revenue	0.01	0.06	0.09	0.32	0.76
Gross Profit	0.55	0.93	-0.09	-0.32	-0.76
Selling, General & Admin	1.73	2.02	2.05	2.14	2.3
Research & Development	1.74	2.39	2.61	2.81	4
Other Operating Expenses	0	-1.02	-0.03	-0.03	-0.13
Operating Expenses	3.47	3.39	4.64	4.93	6.17
Operating Income	-2.93	-3.43	-4.67	-4.96	-6.3
Interest Income	0	0.16	0	0	0.02
Interest Expense	-0.22	0.16	0.96	1.75	1.46
Other Expense / Income	0.41	0.13	-0.09	-0.03	-0.81
Pretax Income	-3.12	-3.55	-5.54	-6.68	-6.92
Income Tax	-0.02	-0	0.96	1.75	1.46
Net Income	-3.1	-3.55	-6.5	-8.43	-8.38
Shares Outstanding (Basic)	420	419	408	393	387
Shares Outstanding (Diluted)	420	419	408	393	387
Shares Change	0.01%	2.76%	3.81%	1.72%	1.11%
EPS (Basic)	-0.01	-0.01	-0.02	-0.02	-0.02
EPS (Diluted)	-0.01	-0.01	-0.02	-0.02	-0.02
Free Cash Flow	-2.57	-3.04	-1.01	-4.09	-6.19
Free Cash Flow Per Share	-0.01	-0.01	-0.00	-0.01	-0.02
Gross Margin	98.40%	93.55%	-	-	-
Operating Margin	-524.55%	-346.59%	-	-	-
Profit Margin	-556.16%	-359.36%	-	-	-
Free Cash Flow Margin	-461.17%	-307.52%	-	-	-
EBITDA	-2.92	-3.38	-4.62	-4.69	-5.46
EBITDA Margin	-522.95%	-341.80%	-	-	-
Depreciation & Amortization	0.01	0.01	0.01	0.24	0.69
EBIT	-2.93	-3.39	-4.64	-4.93	-6.14
EBIT Margin	-524.55%	-342.90%	-	-	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.